Is there any domestic version of bimetinib/bemetinib in China?

Binimetinib is a drug for the treatment of melanoma and lung cancer. It has not yet received marketing approval from the China National Medical Products Administration (NMPA), so it is still unmarketed in the Chinese mainland market. Since no original drug has entered the domestic market, the drug does not have coverage records in China’s medical insurance catalog. In other words, if patients need to use bimetinib, they can only obtain it at their own expense through overseas medical treatment, cross-border drug purchase or third-party platforms, and they must bear the full cost of the drug, which is a major financial challenge for many patients.

Currently there is no generic version of bimetinib in China, mainly because the drug is still within the scope of patent protection, andThe research and development of MEK inhibitors in China is still in the early stages. Although some local pharmaceutical companies are developing MEK target drugs, they are still far away from clinical application. In the clinical trial stage, even if the drug shows good efficacy, it still needs to go through a long approval process before it can be put on the market, involving safety assessment, registration trials, and medical insurance negotiations.

It is worth noting that some neighboring countries such as Laos, India, Bangladesh, etc. have launched generic versions of bimetinib. The ingredients of these generic drugs are basically the same as the original drugs. However, due to different production standards and regulatory systems, it is recommended that patients must obtain it through formal channels and use it under the guidance of professional doctors.

The domestic medical community and regulatory authorities are increasingly paying attention to the promotion and popularization of targeted therapies. In the future, they do not rule out the introduction of original drugs, promoting the development of generic drugs, or cooperating with international pharmaceutical companies to allow bimetinib to enter the Chinese market. Once the drug is included in the medical insurance catalog, it will significantly improve the treatment accessibility for domestic BRAF mutant melanoma patients and provide new treatment options for other solid tumors. Therefore, paying attention to drug approval dynamics and policy progress is of great significance for patients to rationally plan treatment paths.

Reference materials:https://go.drugbank.com/drugs/DB11967